Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects

Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have focused on immunotherapy for HCC. Immunotherapies have shown promising clinical outcomes in several types of cancers a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Cheng, Li, Yirun, Yang, Jing, Jin, Shengxi, Chen, Guoqiao, Li, Duguang, Fan, Xiaoxiao, Lin, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039369/
https://www.ncbi.nlm.nih.gov/pubmed/33854960
http://dx.doi.org/10.3389/fonc.2021.589680
_version_ 1783677574994460672
author Zhong, Cheng
Li, Yirun
Yang, Jing
Jin, Shengxi
Chen, Guoqiao
Li, Duguang
Fan, Xiaoxiao
Lin, Hui
author_facet Zhong, Cheng
Li, Yirun
Yang, Jing
Jin, Shengxi
Chen, Guoqiao
Li, Duguang
Fan, Xiaoxiao
Lin, Hui
author_sort Zhong, Cheng
collection PubMed
description Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have focused on immunotherapy for HCC. Immunotherapies have shown promising clinical outcomes in several types of cancers and potential therapeutic effects for advanced HCC. In this review, we summarize the immune tolerance and immunotherapeutic strategies for HCC as well as the main challenges of current therapeutic approaches. We also present alternative strategies for overcoming these limitations.
format Online
Article
Text
id pubmed-8039369
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80393692021-04-13 Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects Zhong, Cheng Li, Yirun Yang, Jing Jin, Shengxi Chen, Guoqiao Li, Duguang Fan, Xiaoxiao Lin, Hui Front Oncol Oncology Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have focused on immunotherapy for HCC. Immunotherapies have shown promising clinical outcomes in several types of cancers and potential therapeutic effects for advanced HCC. In this review, we summarize the immune tolerance and immunotherapeutic strategies for HCC as well as the main challenges of current therapeutic approaches. We also present alternative strategies for overcoming these limitations. Frontiers Media S.A. 2021-03-29 /pmc/articles/PMC8039369/ /pubmed/33854960 http://dx.doi.org/10.3389/fonc.2021.589680 Text en Copyright © 2021 Zhong, Li, Yang, Jin, Chen, Li, Fan and Lin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhong, Cheng
Li, Yirun
Yang, Jing
Jin, Shengxi
Chen, Guoqiao
Li, Duguang
Fan, Xiaoxiao
Lin, Hui
Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
title Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
title_full Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
title_fullStr Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
title_full_unstemmed Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
title_short Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
title_sort immunotherapy for hepatocellular carcinoma: current limits and prospects
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039369/
https://www.ncbi.nlm.nih.gov/pubmed/33854960
http://dx.doi.org/10.3389/fonc.2021.589680
work_keys_str_mv AT zhongcheng immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects
AT liyirun immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects
AT yangjing immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects
AT jinshengxi immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects
AT chenguoqiao immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects
AT liduguang immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects
AT fanxiaoxiao immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects
AT linhui immunotherapyforhepatocellularcarcinomacurrentlimitsandprospects

Ejemplares similares